By comparing the gene expression of these tumors, we explored biomarkers for predicting the castration resistance of prostate cancer and found that the α2 chain of interleukin‐13 receptor (IL13Rα2) was highly expressed in castration‐resistant models. The gene discussed is IL13RA2; the disease is prostate carcinoma.